Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VBP

ABPI London offices

ABPI bid to overturn NICE’s budget impact rules fails

One in five new medicines would have been affected by the rejected policy

- PMLiVE

Janssen’s Imbruvica fails to win NICE backing in lymphoma

But the agency recommends it on the CDF for another type of cancer

Hunt vs Hawking: We’ll call it a draw

Who won the recent bout between Jeremy Hunt and Stephen Hawking? We'll let you score the cards.

Life Healthcare Communications

What will the NHS’s Capped Expenditure Process (CEP) mean for pharma?

Paul Midgley, Director of NHS Insight at Wilmington Healthcare, explains how pharma should tailor its approach

Wilmington Healthcare

Bristol-Myers Squibb (BMS) building

NICE says OK to Opdivo for lung cancer via CDF

Comes after BMS drops the price of its PD-1 inhibitor

Merck to co-lead new oncology big data alliance

Will work with Project Data Sphere to improve cancer care

- PMLiVE

NICE: We’re the institute of ‘yes’

But Meindert Boysen says affordability conversations with pharma need to happen earlier

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

Life at the end of the Brexit tunnel

A new proposal to maintain the UK as a benchmark of excellence in Life Sciences

Life Healthcare Communications

- PMLiVE

NICE backs Europe’s first stem cell therapy

Holoclar is approved for routine use in patients with LSCD

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s leukaemia drug Besponsa

Firm plans to appeal the final appraisal determination on its orphan drug

- PMLiVE

NICE expands Merck KGaA’s Erbitux reach

Backs the medicines use for patients with SCCHN

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links